Sale

Rheumatoid Arthritis Therapeutics Market

Global Rheumatoid Arthritis Therapeutics Market Share, Size, Growth, Analysis; By Product Type: Biologics, Non-Biologics; By Sales Type: Prescription, Over-the-Counter (OTC), Others; By Route of Administration: Oral, Parenteral; By Distribution Channel; Regional Analysis; Supplier Landscape; Key Trends and Developments in the Market; 2024-2032

Global Rheumatoid Arthritis Therapeutics Market Outlook

The rheumatoid therapeutics market size was USD 30.86 billion in 2023, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032 to reach value of USD 46.25 billion by 2032.

 

Key Trends in the Market

Rheumatoid arthritis or RA is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. Compared to osteoarthritis, rheumatoid arthritis could also deleteriously affect the eyes, lungs, heart, kidneys, salivary glands, and other vital organs.

 

  • Rheumatoid arthritis therapeutics sees the involvement of Janus-Kinase inhibitors and Tumour Necrosis Factor involvement in drugs as the primary evangelists of the rheumatoid arthritis therapeutics market globally. Moreover, a plethora of drugs innovated to cater to the disease bolsters the firm hold of the market.
  • Disease-modifying antirheumatic drugs (DMARDs), the primary counter-medicines to combat the disease, are maintaining a strong position in the market, despite the introduction of novel drugs.
  • A surge in the obese population, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the rheumatoid arthritis therapeutics market.
  • Biopharmaceuticals have been and will be one of the most substantial market drivers for the global rheumatoid arthritis market in the years to come. Biopharmaceuticals would fortify sales in the forthcoming years, having played vital roles in eradicating the disease's severity across many countries. Although the drugs are quite expensive as they are still in the market skimming period, market penetration will assuage the high prices once the firmness grows.

 

Global Rheumatoid Arthritis Market Analysis

Based on the product type, the market can be segmented into biologics, and non-biologics. The non-biologics segment is further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), and synthetic disease-modifying antirheumatic drugs (SDMARDs). Based on sales type, the market is bifurcated into prescription and over-the-counter (OTC).

 

On the basis of distribution channel, the market could be branched into hospital pharmacies, retail pharmacies, and online. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global rheumatoid arthritis therapeutics market, covering its competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.

 

  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB SA.
  • Gilead Sciences, Inc.
  • Others

 

Market Share by Product Type

Rheumatoid arthritis therapeutics has seen a distended disruption across the world pinned to the change in lifestyle that has exacerbated the underlying symptoms. Owing to this, medications and prophylaxis have seen a motley of options of biologics and non-biologics. Biologics have taken a significant chunk as a prophylactic alternative over the years.

 

Biologics have surpassed the non-biologics in the rheumatoid arthritis therapeutics market behind despite their frugal costs and budget-friendly advantage over biologics. The dominance could be ligated to the therapeutic adeptness of biologics as per various rheumatoid arthritis patients.

 

However, the non-biologics couldn't be wholly uprooted as it has been in the therapeutic market significantly longer than biologics. Moreover, not everyone can afford the advanced treatments of biologics; therefore, non-biologics find its user database cemented with the proletarian spectrum of the population.

 

Market Share by Region

Rheumatoid arthritis therapeutics have been witnessing colossal growth in North America due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the region in the rheumatoid arthritis therapeutics market. Also, the vast budget share in the arena of rheumatoid arthritis therapeutics equally raises its market share.

 

Europe has seen significant propellants in the form of novel drugs innovation, advanced healthcare alternatives to grapple with the disease, and an increment in the cases. In the Asia Pacific, the stanchioning infrastructure of healthcare, increasing awareness, and high adoption of biologics have catalysed the therapeutic market.

 

Contrary to the developing strides in North America, Europe, and Asia Pacific, the rheumatoid arthritis therapeutics market coverage hasn't matched the pace in Latin America, the Middle East, and Africa. However, growth could be anticipated after a few years on the grounds of increased awareness.

 

rheumatoid arthritis therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Pfizer Inc., headquartered in New York, United States, was founded in 1849. It has been instrumental in elevating the global pharmaceutical and therapeutic markets with its innovation and substantial league of drugs. The company covers a phenomenal market share across a vast gamut of therapeutics for reducing cholesterol, inflammation, and so on. It has been a major contributor to the expansion of therapeutics for rheumatoid arthritis.

 

Amgen Inc. is based out of California in the United States, and was founded in 1980. A leading biotechnology organisation, Amgen Inc., caters to oncology, bone health, cardiovascular disease, nephrology, neuroscience, and inflammation. The focus area of inflammation considers relevant disorders that give rise to inflammatory disorders, such as rheumatoid arthritis. It’s biologics category counters the disease and its aftermath.

 

Bristol-Myers Squibb Company is headquartered in New York, United States, and has been a vital contributor to the pharmaceutical and healthcare industry since its inception in 1989. The company is a merger between Bristol-Myers and Squibb and has made significant breakthroughs in neurology, haematology, cardiovascular diseases, and immunology, among others. Immunology forms the basis of the company's study and research endeavours of rheumatoid arthritis therapeutics.

 

Other market players include F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Sales Type
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Breakup by Product Type
  • Biologics
  • Non-Biologics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
    • Others
Breakup by Sales Type
  • Prescription
  • Over The Counter (OTC)
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Breakup by End User
  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie.
  • Eli Lilly and Company

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Rheumatoid Arthritis Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Rheumatoid Arthritis Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Rheumatoid Arthritis Epidemiology (2016-2031)
    5.3    Europe Rheumatoid Arthritis Epidemiology (2016-2031)
    5.4    Asia-Pacific Rheumatoid Arthritis Epidemiology (2016-2031)
    5.5    Latin America Rheumatoid Arthritis Epidemiology (2016-2031)
    5.6    Middle East & Africa Rheumatoid Arthritis Epidemiology (2016-2031)
6    Global Rheumatoid Arthritis Therapeutics Market Overview 
    6.1    Global Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
7    Global Rheumatoid Arthritis Therapeutics Market Landscape
    7.1    Rheumatoid Arthritis Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Rheumatoid Arthritis Therapeutics: Product Landscape
        7.2.1    Analysis by Product
        7.2.2    Analysis by End User
8    Rheumatoid Arthritis Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Rheumatoid Arthritis Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Rheumatoid Arthritis Therapeutics Market Segmentation
    11.1    Global Rheumatoid Arthritis Therapeutics Market by Product Type
        11.1.1    Market Overview
        11.1.2    Biologics
        11.1.3    Non-Biologics
            11.1.3.1    Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
            11.1.3.2    Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
            11.1.3.3    Others
    11.2    Global Rheumatoid Arthritis Therapeutics Market by Sales Type
        11.2.1    Market Overview
        11.2.2    Prescription
        11.2.3    Over The Counter (OTC)
        11.2.4    Others
    11.3    Global Rheumatoid Arthritis Therapeutics Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
    11.4    Global Rheumatoid Arthritis Therapeutics Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online
    11.5    Global Rheumatoid Arthritis Therapeutics Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals & Clinics
        11.5.3    Research and Academic Laboratories
        11.5.4    Others
    11.6    Global Rheumatoid Arthritis Therapeutics Market by Region
        11.6.1    Market Overview
        11.6.2    North America
        11.6.3    Europe 
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Rheumatoid Arthritis Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Rheumatoid Arthritis Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Rheumatoid Arthritis Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Rheumatoid Arthritis Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Rheumatoid Arthritis Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Pfizer Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Amgen Inc. 
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Bristol-Myers Squibb Company 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    F. Hoffmann-La Roche Ltd
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    UCB S.A.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Gilead Sciences, Inc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Boehringer Ingelheim GmbH
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Novartis International AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Regeneron Pharmaceuticals, Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    AbbVie.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Eli Lilly and Company
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
24    Rheumatoid Arthritis Therapeutics - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The rheumatoid therapeutics market size was USD 30.86 billion in 2023, driven by the increasing prevalence of rheumatoid arthritis across the globe.

The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032 to reach value of USD 46.25 billion by 2032.

The rise in reported cases of rheumatoid arthritis, introduction of novel drugs in the therapeutic market, and increasing awareness are the major market drivers.

A surge in the usage of biopharmaceuticals, increased accessibility of therapeutics, and breakthroughs in the domain of immunology and anti-inflammatory prophylaxis are the key trends in the market.

The key distribution channels are hospital pharmacies, retail pharmacies, and online channels.

The key players in the global rheumatoid arthritis therapeutics market are Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.

Yes, rheumatoid arthritis doesn't have any permanent cure as of now. Hence, medicines must be taken consistently to mitigate the symptoms.

Rheumatoid arthritis tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER